semaglutide nih An NIH/NIDA study finds that may help people quit smoking. New use of semaglutide was associated with a lower risk for medical care related to tobacco use disorder (TUD) in smokers Semaglutide for the treatment of

Observational studies and clinical practice suggest that these patients would benefit more from an LSG or RYBG intervention than LAGB, although there are currently no published randomised clinical trials showing the superiority of one procedure in terms of long-term glycaemic control and remission of T2DM [10, 34]

The initial dose might start at 0.25 mg per week, increasing gradually based on the patients response and tolerance

They can be talked about without reducing a person to their drinking

There are better competitors out there

At present, semaglutide is licensed for people with type 2 diabetes who have not responded well to other treatments